The U.S. Food and Drug Administration (FDA) approved the BTL Vanquish (BTL Industries) device for circumferential reduction of the abdomen area. The platform features a panel array that emits selective RF energy with the largest spot size in the industry to treat the entire core in one application (without touching patients’ skin). It creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue.
“FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference,” said Andrea Morrison, BTL director of clinical development. “BTL is proud to offer patients a comfortable, affordable and noninvasive body shaping experience. This regulatory milestone underscores BTL’s commitment to deliver meaningful solutions to aesthetic patient care.”
For more information, visit www.btlaesthetics.com.
Photo copyright Getty Images.
